Condition: Lymphoma · Advanced Prostate Cancer · Advanced Breast Cancer · Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Multicenter, observational, prospective, study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the usual clinical practice are planned for the study.
This description comes directly from the study's public registry record.
Oriana Nanni · +390543739266 · cc.ubsc@irst.emr.it
Bernadette Vertogen · +390544286058 · cc.ubsc@irst.emr.it
Always discuss trial participation with your own doctor first.
| IRCCS - Azienda Ospedaliero-Universitaria di Bologna - Policlinico di S. Orsola | Bologna, BO, Italy | Recruiting |
| IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. | Meldola, FC, Italy | Recruiting |
| IRCCS Istituto Europeo di Oncologia S.r.l. | Milan, MI, Italy | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06895291